Do you have Crohn’s?

Research studies are enrolling now.

Those who qualify may receive*:

  • Study-related care from local doctors and specialists with no waiting lists

You could help make a difference for others struggling with Crohn’s.

Ready to get started? Click Here.

You may qualify for local research studies!

Crohn’s disease is an inflammatory bowel disease. It can affect any part or all of your digestive tract. In Crohn’s, there are healthy parts of the intestine along with inflamed areas. Symptoms, which can be mild to severe and vary over time, include frequent or recurring diarrhea, abdominal pain and cramping, fatigue, reduced appetite, unexplained weight loss or fever. Crohn’s can affect your daily life. Crohn’s flare-ups, or active symptoms, can be uncomfortable, painful, and even embarrassing. Flares stop many people from taking part in daily activities, affecting work, income and social interactions. While some people may find their symptoms are managed by their medications, many others do not find relief. Better treatment options are needed for people who suffer with Crohn’s. Right now, local doctors are looking for people who have Crohn’s to participate in research studies.

You may qualify for local research studies. But don’t delay — space is limited!

* In a research study, the participants may receive investigational study product or may receive an inactive substance, or placebo, depending on the study design. Participants receive study-related care from a doctor/research team for the duration of the study. For studies that offer compensation, reasonable payments will be made for participation. The length of the study may vary.

Ready to get started?

Click Here.

How does it work?

1

Tell us a little bit about yourself

2

Answer some questions about your health

3

We will connect you to available studies in your area

Just takes a few minutes

AcurianHealth

AcurianHealth helps connect people with research studies that offer treatment under development. Since 1998, AcurianHealth has referred 1 million study candidates to 800 studies in 70 countries.